United States Capitol, Washington DC

19TH INTERNATIONAL CONFERENCE

SCWD 2026

Scientific programme

Cachexia, Sarcopenia
& Wasting Disorders

December 10–12, 2026 Washington, DC · In person

  • December 10–12, 2026
  • Washington, DC
  • In person

From emerging therapies to AI-assisted assessment. Join the scientific conversation shaping the next chapter of muscle health.

Scientific programme

Three days of basic science, translational research and clinical discussion. Browse the sessions, chairs and presentation topics below.

Programme updated 19 November 2026. Speakers, timings and session details remain subject to confirmation.

Programme subject to change.

DEC10DAY 1

Thursday, 10 December 2026

TIMEHALL AHALL B
08:30–09:30
SESSION 1 · HALL A · Basic

Epigenetics of sarcopenia and cachexia

Chairs
Brittany Counts, USA; Russell Hepple, USA

  • Abnormal DNA methylation and altered transcriptome in muscle five years after critical illnessIlse Vanhorebeek, Belgium
  • Nicholas Greene
    Skeletal muscle methylome-transcriptome disruptions during the onset and progression of colorectal cancer-induced cachexiaNicholas Greene, USA
  • Giuseppina Caretti
    BET inhibitors for sarcopeniaGiuseppina Caretti, Italy
  • Presentation title to be announcedSpeaker to be announced
  • Discussion
SESSION 2 · HALL B · Translational

Kidney, kidney cancer, and cachexia

Chairs
Srinivasan Dasarathy, USA; Angela Wang, Singapore

  • Marilia Seelaender
    Cachexia as multi-organ diseaseMarilia Seelaender, Brazil
  • Joanna Lima
    Tracing Early Oncogenic Events in Renal Cancer: Implications for Cachexia and HIF SignalingJoanna Lima, Brazil
  • James Brugarolas
    HIF-2α–driven paraneoplastic syndromes in aggressive kidney cancer: linking PTHrP, hypercalcemia, and cachexiaJames Brugarolas, USA
  • Robert Mak
    The inflammasome connection: NLRP3 at the Crossroads of Cancer and CKD CachexiaRobert Mak, USA
  • Discussion
09:40–10:40
SESSION 3 · HALL A · Basic

Loss of protein quality control in muscle aging and disease

Chairs
Denis Guttridge, USA; Ilse Vanhorebeek, Belgium

  • Volker Adams
    Protein degradation in disease – insights from human biopsiesVolker Adams, Germany
  • Benjamin Miller
    Protein aggregation in muscle disease and agingBenjamin Miller, USA
  • Tracy Anthony
    Integrated stress response in protein quality control in muscleTracy Anthony, USA
  • Fabio Demontis
    Insolubilome in muscle agingFabio Demontis, USA
  • Discussion
SESSION 4 · HALL B · Basic

Neuromuscular impairments in cachexia and sarcopenia

Chairs
Andrea Bonetto, USA; Richard Lieber, USA

  • Joshua Huot
    Impaired motor unit connectivity in cancerJoshua Huot, USA
  • Marco Narici
    New insights on neuromuscular junction instability with inactivityMarco Narici, Italy
  • Human neuromuscular organoids mimic cancer-induced muscle wastingPietro Chiolerio, Italy
  • Bumsoo Han
    A microphysiological model of muscle denervation in pancreatic cancer cachexiaBumsoo Han, USA
  • Discussion
10:50–11:50
SESSION 5 · HALL A · Translational

Connecting geroscience and osteosarcopenia

Chairs
Marco Brotto, USA; Fabrizio Pin, USA

  • The role of the ribosomes in muscle and bone healthSpeaker to be announced
  • Targeting optimal recovery in fragility fracture patients with co-existing osteosarcopeniaRonald Man Yeung Wong, Hong Kong
  • Gustavo Duque
    Tryptophan metabolites as regulators of bone and muscle healthGustavo Duque, Canada
  • Cytoskeletal integrators of inflammaging drive osteosarcopeniaChris Ward, USA
  • Discussion
SESSION 6 · HALL B · Basic

Systems biology of cachexia

Chairs
Mauricio Berriel Diaz, Germany; Erin Talbert, USA

  • Cross-study meta-analysis of the cancer cachexia transcriptomeYoshiaki Tanaka, Canada
  • Dr. Min Deng
    Functional interrogation of the pancreatic cancer cachexia secretomeDr. Min Deng, NorwayResearcher, Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital
  • Cachexia multi-ome analysis reveals early perturbations in adipose tissueHonglei Ji, Germany
  • Laure Bindels
    The gut microbiome and cancer cachexiaLaure Bindels, Belgium
  • Discussion
12:00–12:50

Lunch Time Symposium - Supported by Pfizer Inc

13:00–14:00
SESSION 7 · HALL A

Opening session

Chairs
Teresa Zimmers, USA; Stefan Anker, Germany

  • Stefan Anker
    WelcomeStefan Anker, Germany
  • Denis Guttridge
    “Prometheus” basic science keynote lecture · Cachexia and the immune tumor macroenvironmentDenis Guttridge, USA
  • Jeffrey Crawford
    “Hippocrates” clinical science keynote lecture · Cancer and cachexia: an oncologist’s perspectiveJeffrey Crawford, USA
  • Stefan Anker
    JCSM UpdateStefan Anker, Germany
14:15–15:30
SESSION 8 · 14:15–15:40 · HALL A · Clinical

Multi-organ wasting during incretin treatment

Chairs
Andrew Coats, Australia; Javed Butler, USA

Panelists
David Glass, USA; Stefan Anker, Germany

  • Jennifer Linge
    Skeletal muscle loss during GLP-1RA based therapies: size of the problem?Jennifer Linge, Sweden
  • How does weight cycling affect different tissue compartments?Joseph Brozinick, USA
  • Markus Anker
    Do incretin mimetics cause cardiac atrophy?Markus Anker, Germany
  • Maurizio Muscaritoli
    Can high protein diet prevent muscle wasting?Maurizio Muscaritoli, Italy
  • Kristoffer Jensen Kolnes
    Effect of GLP-1RA and amylin-based assets on body composition and physical function and related outcomesKristoffer Jensen Kolnes, Denmark
  • Julio Rosenstock
    Muscle anabolics during and after GLP-1RA therapy: trial resultsJulio Rosenstock, USA
  • Discussion
SESSION 9 · HALL B · Translational

Mitochondrial dysfunction as a therapeutic target in cachexia: exploring disease-specific mechanisms and shared pathways

Chairs
Volker Adams, Germany; Scott Bowen, UK

  • Tumor-driven mitochondrial dysfunction in cancer cachexiaPaola Costelli, Italy
  • Mitochondrial dysfunction in age associated cachexiaRussell Hepple, USA
  • Mitochondrial function as therapeutic target in cachexiaBeatrice Vahle, Germany
  • Novel pharmacological approaches to target mitochondriaTienush Rassaf, Germany
  • Discussion
15:30–16:30

Break

15:35–16:25
15:35–16:25 · POSTER AREA

Poster viewing 1

Each presentation: 2 minutes + 2 minutes discussion

  • Poster session 1.1 · Cachexia – animal models II (posters 2-12 to 2-23)Chairs: Marilia Seelaender, Jochen Springer
  • Poster session 1.2 · Cancer cachexia I (posters 3-01 to 3-11)Chairs: Mauricio Berriel Diaz, Nicholas Greene
  • Poster session 1.3 · Muscle Wasting & Sarcopenia I (posters 4-01 to 4-12)Chairs: Joe Chakkalakal, Nicole Welch
  • Poster session 1.4 · Muscle Wasting & Sarcopenia III (posters 4-25 to 4-36)Chairs: To be announced
HALL B

Rapid fire abstracts Session 1

Chairs
Marcus Goncalves, USA; Agata Mossakowski, Germany; Annemie Schols, Netherlands

Each presentation: 3 minutes + 2 minutes discussion

  • 15:35–15:40 · Exercise effects on lean mass and strength when added to GLP-1RA therapy for obesity treatment: the M3 study (6-04)Renee J. Rogers, USA
  • 15:40–15:45 · From patient voice to clinical endpoints: Developing and validating a fit-for-purpose clinical outcome assessment battery for sarcopenia (6-05)David Cella, USA
  • 15:45–15:50 · Impact of intravenous iron supplementation on physical performance in patients with ME/CFS and iron deficiency: the IRON-ME study (7-05)Nadja Jauert, Germany
  • 15:50–15:55 · Regenerating skeletal muscle after cancer therapy-induced tissue wasting (7-07)Michael Hicks, USA
  • 15:55–16:00 · Protective effect of Zn-specific chelator N,N,N′,N′-Tetrakis-(2-pyridylmethyl) ethylenediamine on chronic kidney disease-induced myopathy (7-08)Jia-Hua Jhuang, Taiwan
  • 16:00–16:05 · Divergent systemic and intratumoral immunometabolic effects of Interleukin-4 associated with the prevention of cancer cachexia (7-09)Giacomo Rubini, Italy
  • 16:05–16:10 · Development and characterization of preclinical rodent models of skeletal muscle atrophy (7-10)Kylie Heitman, USA
  • 16:10–16:15 · Melanocortin agonism drives lean-mass-sparing weight loss with increased energy expenditure in animal models of obesity (7-12)Allison Gardner, USA
16:30–17:45
SESSION 10 · HALL A · Translational

Biology, bulk, and function. What is the intersection in cancer cachexia?

Chairs
Jose Garcia, USA; Joshua Huot, USA

  • Richard L. Lieber
    How neural and physiologic mechanisms integrate to dictate muscle function: translational examplesRichard L. Lieber, USA
  • Ishan Roy
    Distinguishing functional decline and recovery: preclinical and clinical lessons in cachexiaIshan Roy, USA
  • William Evans
    Muscle mass is not enough: distinct roles for muscle quality and mass in functionWilliam Evans, USA
  • Brittany Counts
    Muscle remodeling in cachexia: mechanisms linking cellular biology to contractile functionBrittany Counts, USA
  • Discussion
SESSION 11 · HALL B · Clinical

Muscle disorders in acute medical care

Chairs
Wolfram Doehner, Germany; Reshma Merchant, Singapore

  • Muscular disease in the acute medical care setting – update 2026Joerg C. Schefold, Switzerland
  • Skeletal muscle dysfunction during exercise in Long COVIDDavid Systrom, USA
  • Neuromuscular dysfunction in critical illness: Progress in understanding and implications for recoveryStephanie Hiser, USA
  • Suggested clinical approaches to acute muscle wasting in the critically illStefan Schaller, Austria
  • Discussion
17:50–18:40
INDUSTRY SYMPOSIUM · HALL A

Targeting the biology of cachexia in cancer: from disease burden to clinical impact

Chairs
Stefan Anker, Germany; Jeffrey Crawford, USA

  • Markus Anker
    Cancer cachexia in non-small cell lung cancer: epidemiology, prevalence and clinical consequencesMarkus Anker, Germany
  • Andrew Coats
    A novel multimodal therapeutic approachAndrew Coats, Australia
  • Evaluating S-pindolol in patients with NSCLC and cancer cachexiaUwe Pelzer, Germany
  • Panel discussion

SCWD symposium supported by Actimed Therapeutics

18:45–19:45

Welcome reception · Joint poster viewing

Join the opening conversations.

SCWD 2026 · Washington, DC · December 10–12

Register in person

DEC11DAY 2

Friday, 11 December 2026

TIMEHALL AHALL B
08:30–09:30
SESSION 12 · HALL A · Clinical

Cachexia in critical illness

Chairs
Stefan Schaller, Austria; Angela Wang, Singapore

  • Kamyar Kalantar-Zadeh
    Cachexia in CKD and AKIKamyar Kalantar-Zadeh, USA
  • Wolfram Doehner
    StrokeWolfram Doehner, Germany
  • Orlando Laitano
    Cachexia in sepsisOrlando Laitano, USA
  • Leonidas Koniaris
    Cachexia induced by liver growth and injuryLeonidas Koniaris, USA
  • The effect of sleep abnormalities on body compositionMarcello Maggio, Italy
  • Discussion
SESSION 13 · HALL B · Clinical

COACH-ED: crosstalks on diagnosing and treating cancer cachexia

Chairs
Maurizio Muscaritoli, Italy; Richard Skipworth, UK

  • Diagnosing and managing cachexia in the oncology and palliative care settingEgidio Del Fabbro, USA
  • Paula Ravasco
    Beyond calories: nutrients as active therapeutics in oncology carePaula Ravasco, Portugal
  • Clinical trials and innovation in cancer cachexia careUwe Pelzer, Germany
  • Jose Garcia
    COACH-ED: program outcomes and future directions – the road aheadJose Garcia, USA
  • Discussion
09:30–10:30

Break

09:35–10:25
09:35–10:25 · POSTER AREA

Poster viewing 2

Each presentation: 2 minutes + 2 minutes discussion

  • Poster session 2.1 · Cachexia (posters 1-01 to 1-10)Chairs: Giuseppina Caretti, Neil Greening
  • Poster session 2.2 · Therapeutic Development (clinical & pre-clinical) (posters 7-01 to 7-14)Chairs: David Glass, Henning Langer
  • Poster session 2.3 · Cancer cachexia II (posters 3-12 to 3-22)Chairs: Tracy Anthony, Ed Reznik
  • Poster session 2.4 · Cachexia – animal models III (posters 2-24 to 2-36)Chairs: Tobias Janowitz, Jochen Springer
09:35–10:15 · HALL B

Rapid fire abstracts Session 2

Chairs
Faisal Beg, Canada; Grace Kulik, USA

Each presentation: 3 minutes + 2 minutes discussion

  • 09:35–09:40 · High-throughput 3D light-sheet imaging of mouse hindlimbs enables skeletal muscle morphometrics in muscle wasting models (4-04)Matteo Oliverio, Denmark
  • 09:40–09:45 · MitoXcel™ geropeptide PTC-2105 attenuates terminal lean-mass decline in aged mice and semaglutide-associated lean-mass loss (4-09)Kevin Slawin, USA
  • 09:45–09:50 · Identifying a protective role for UBR-box E3 ubiquitin ligases in age-related skeletal muscle wasting through the NRF2/Hmox1 pathway (4-14)Emma J. Sanderson, USA
  • 09:50–09:55 · Single-nucleus multi-omics reveals reversible molecular signatures in exercise-intolerant skeletal muscle of patients with heart failure with preserved ejection fraction (4-19)Maya Bose, USA
  • 09:55–10:00 · Discordance between formula-estimated and DXA-derived body composition highlights the prognostic role of fat mass in men with chronic heart failure (4-25)Ryosuke Sato, Germany
  • 10:00–10:05 · Conversion to high urinary titin marks concurrent loss of muscle strength, but not muscle mass, in type 2 diabetes: a 3-year prospective cohort study (4-38)Michio Shimabukuro, Japan
  • 10:05–10:10 · Blood-based biomarkers of biological aging and risk of incident sarcopenia in community-dwelling older adults: findings from the Health ABC study (4-43)Danae C. Gross, USA
  • 10:10–10:15 · Mitochondrial respiratory capacity of Skeletal muscle is reduced in patients with ME/CFS: high-resolution respirometry analysis from the VADYS-ME study (4-48)Tilman Kalk, Germany
10:30–11:30
SESSION 14 · 10:30–11:20 · HALL A

SCWD scientific session sponsored by Nestlé

Chairs
To be announced

  • Presentations to be announced.
SESSION 15 · HALL B · Translational

Biomarkers and mechanisms in cancer cachexia

Chairs
Erin Talbert, USA; Eileen White, USA

  • Marcus Goncalves
    JAK1/2 inhibition delays cachexia and improves survival through increased food intakeMarcus Goncalves, USA
  • Teresa Zimmers
    Responder analysis in the PACTO trialTeresa Zimmers, USA
  • Andrew Judge
    Unmasking complement: a causal pathway in cancer-induced muscle lossAndrew Judge, USA
  • Plasma Hsp90 Level correlates with cachexia and shorter survival in cancer patientsYi-Ping Li, USA
  • Discussion
11:45–13:00
SESSION 16 · HALL A · Clinical

Cancer cachexia emerging therapies

Chairs
Jeffrey Crawford, USA; Uwe Pelzer, Germany

Panelists
John Borg, Malta; Marina Zemskova, USA

  • Dan Marks
    MC3/MC4R inhibition for cachexiaDan Marks, USA
  • Eric Roeland
    GDF15 inhibition to reduce cachexia and promote anti-tumor therapyEric Roeland, USA
  • Andrew Coats
    S-pindololAndrew Coats, Australia
  • Presentation title to be announcedSpeaker to be announced
  • Discussion
SESSION 17 · HALL B · Clinical

Cachexia in chronic illness: update 2026

Chairs
Kamyar Kalantar-Zadeh, USA; Annemie Schols, Netherlands

  • Cachexia in heart failure – still an issueMarija Zdravkovic, Serbia
  • Cachexia in Type 2 Diabetes Mellitus – update 2026Mitja Lainscak, Slovenia
  • COPDNeil Greening, UK
  • Srinivasan Dasarathy
    Cachexia in MASH / MASLDSrinivasan Dasarathy, USA
  • Discussion
13:00–14:15

Lunch break

13:10–14:00
INDUSTRY SYMPOSIUM · HALL A

The emerging role of ACTAs across muscle wasting disorders

Chairs
Stefan Anker, Germany; Andrew Coats, Australia; Marija Zdravkovic, Serbia

  • Henning Langer
    S-pindolol: preclinical evidence in the context of GLP-1 treatmentHenning Langer, Germany
  • The impact of various muscle anabolic on lean / fat mass changes in response to incretinsMitja Lainscak, Slovenia
  • S-oxprenolol in ALS: addressing an unmet need in progressive muscle lossAngelico Carta, Italy
  • Panel discussion

SCWD symposium supported by Actimed Therapeutics

14:15–15:30
SESSION 18 · HALL A · Translational

Pediatric cancer cachexia

Chairs
Erin Talbert, USA; Paola Costelli, Italy

  • Biomarkers of the systemic response to cancer in childrenDaniel Runco, USA
  • Joe Chakkalakal
    Postnatal neuromuscular growth and the consequences of pediatric cancer therapiesJoe Chakkalakal, USA
  • Pediatric CHOP chemotherapy acutely disrupts satellite-cell dynamics and blunts muscle mass in a sex-specific mannerMichael Wiggs, USA
  • Richard Skipworth
    The surgeon’s viewRichard Skipworth, UK
  • Discussion
SESSION 19 · HALL B · Clinical

Defining cachexia, sarcopenia, and frailty

Chairs
Reshma Merchant, Singapore; Gustavo Duque, Canada

  • Ben Kirk
    The conceptual and operational definition of sarcopeniaBen Kirk, Australia
  • Measuring muscle quantity and quality, the options: DEXA, CT, MRILars Johansson, Sweden
  • From sarcopenia to frailty and cachexia: clinical phenotypes, overlap, and outcomesPaul Coen, USA
  • Sarcopenic obesity in CKD: a difficult entityAngela Wang, Singapore
  • Discussion
15:30–16:30

Break

15:35–16:25
15:35–16:25 · POSTER AREA

Poster viewing 3

Each presentation: 2 minutes + 2 minutes discussion

  • Poster session 3.1 · Muscle Wasting & Sarcopenia IV (posters 4-37 to 4-48)Chairs: Ishan Roy; to be announced
  • Poster session 3.2 · Nutrition and Appetite + Physical Activity and Training (posters 5-01 to 5-04 and 6-01 to 6-06)Chairs: Morten Hostrup; to be announced
15:35–16:25 · HALL B

Rapid fire abstracts Session 3

Chairs
Kamal Awad, USA; Laure Bindels, Belgium; Yi-Ping Li, USA

Each presentation: 3 minutes + 2 minutes discussion

  • 15:35–15:40 · Plasma metabolites associated with cachexia in chronic obstructive pulmonary disease (1-05)Archana Yadav, USA
  • 15:40–15:45 · Human neuromuscular organoid for decoding cancer-induced muscle cachexia (1-08)Pietro Chiolerio, Italy
  • 15:45–15:50 · AMPK-endocytosis axis links copper dysregulation to adipose wasting in cancer cachexia (2-07)Honglei Ji, Germany
  • 15:50–15:55 · Tumor Cell-Derived CTGF Remodels the Pancreatic Tumor Microenvironment and Mediates Cancer Cachexia via driving TGF-beta production (2-08)Brittney Poole, USA
  • 15:55–16:00 · Complement component C5a receptor 1 signaling mediates pancreatic cancer-induced muscle pathologies (2-11)Talya Binienda, USA
  • 16:00–16:05 · Olanzapine restores appetite and reduces circulating IL-6 levels in the C-26 model of cancer cachexia (2-14)Rafael Ribeiro Correia, USA
  • 16:05–16:10 · Targeting chemotherapy-induced senescence to preserve skeletal muscle function in cancer cachexia (3-02)Sarah A. Ashiqueali, USA
  • 16:10–16:15 · Symptom burden reveals distinct clinical and biological phenotypes of cancer cachexia beyond weight loss (3-26)Anlan Cao, USA
  • 16:15–16:20 · Dose-limiting treatment toxicity associated to variations of body composition and mortality in patients with metastatic colorectal cancer: numbers at risk in a population-based cohort (4-30)Seil Ko, Canada
  • 16:20–16:25 · A Mitochondrial Phenotype of Premature Sarcopenia in Adult Survivors of Childhood Acute Lymphoblastic Leukemia (4-31)Puneet Bagga, USA
16:30–17:45
SESSION 20 · HALL A

Meet-the-editor session

Moderator
Andrew Coats, Australia

Panelists

  • Journal of Cachexia, Sarcopenia and MuscleStefan Anker, Germany
  • Journal of Gerontology: Biological SciencesGustavo Duque, Canada
  • Skeletal MuscleDavid Glass, USA
  • Clinical Nutrition section of Frontiers in NutritionMaurizio Muscaritoli, Italy
SESSION 21 · HALL B · Clinical

Frailty, sarcopenia and cachexia in chronic liver disease: from mechanisms to therapies

Chairs
Jose Garcia, USA; Sandra Kleiner, Germany

  • Frailty and sarcopenia in patients with cirrhosisNicole Welch, USA
  • Mechanisms of muscle dysfunction in MASLDNicolas Lanthier, Belgium
  • Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosisJennifer Lai, USA
  • GLP-1 agonists for MASLD-associated sarcopenia and muscle dysfunctionGrace Kulik, USA
  • Discussion
18:00–18:50
SESSION 23 · HALL A · Clinical

Cancer Cachexia Endpoints

Chairs
Stefan Anker, Germany; To be announced

  • David Cella
    Meaningful quality of life and patient-reported outcome measures – QLQ-C15-PAL, FACIT-Pal, QLQ-C30 Physical Functioning, PROMIS Physical Function, FAACT-A/CS, FAACT-5IASS, and beyondDavid Cella, USA
  • Physical function outcomes – HGS, SPPB, 6MWTD etc.Eric Roeland, USA
  • Tim Friede
    Hard outcomes for morbidity & mortalityTim Friede, Germany
  • Discussion
SESSION 22 · HALL B · Translational

Data mining the electronic medical record and imaging for diagnostics in cachexia / sarcopenia

Chairs
Ishan Roy, USA; To be announced

  • Faisal Beg
    Automated CT/L3-based body composition pipelines; AI-based opportunistic screening from routine clinical imagingFaisal Beg, Canada
  • Ed Reznik
    Defining cachexia staging and phenotypes using data from a large health systemEd Reznik, USA
  • Comprehensive full-torso automated assessment of body composition on CTRonald Summers, USA
  • Discussion
18:50–19:35

Industry session · Details to be announced

Connect research with clinical practice.

SCWD 2026 · Washington, DC · December 10–12

Register in person

DEC12DAY 3

Saturday, 12 December 2026

TIMEHALL AHALL B
08:00–09:00
SESSION 24 · HALL A

Young Investigators Award Session (YIA)

Chairs / Judges
James Carson, USA; Paola Costelli, Italy; Mitja Lainscak, Slovenia; Reshma Merchant, Singapore; Hidetaka Wakabayashi, Japan; Teresa Zimmers, USA

  • The liver-gut-muscle axis as a therapeutic target for cachexia in head and neck cancer (1-09)Patrick Livingston, USA
  • A consensus progression axis reveals ordered metabolic and signaling reprogramming across organs in PDAC cachexia (1-10)Tingbo Guo, USA
  • The S100A8/A9 complex promotes food intake and prevents adipose tissue loss during cancer cachexia in mice (2-27)Lin Gao, China
  • Circulating and tumour-derived protein signatures of cachexia in pancreatic and periampullary cancer: a 1033-plex analysis of plasma and paired patient-derived tumour organoid secretomes (3-33)Niels Ruber, Netherlands
  • Who shows a greater response to exercise? Sedentary time as a modifier of sarcopenia-related functional response in older women (6-03)Jiwon Yang, Republic of Korea
  • Mitochondrial oxidative phosphorylation complex expression in the tumor microenvironment of cachectic and weight-stable colorectal cancer patients (3-04)Bruna Sottili, Brazil
SESSION 25 · HALL B · Translational

Exercise for cancer cachexia ?!

Chairs
Scott Bowen, UK; Marilia Seelaender, Brazil

  • Resistance vs. aerobic vs. combined training in cancer cachexiaRichard Dunne, USA
  • Pharmacological mimics of exercise: novel strategies to augment muscle mass and functionMorten Hostrup, Denmark
  • Bo Falck Hansen
    Pharmacological possibilities to help patients to move moreBo Falck Hansen, Denmark
  • Phil Atherton
    Exercise versus anabolic drugs for treating sarcopeniaPhil Atherton, UK
  • Discussion
09:00–10:00

Break

09:05–09:55
09:05–09:55 · POSTER AREA

Poster viewing 4

Each presentation: 2 minutes + 2 minutes discussion

  • Poster session 4.1 · Cachexia – animal models (posters 2-01 to 2-11)Chairs: Andrew Judge, Xiling Shen
  • Poster session 4.2 · Cancer cachexia (posters 3-23 to 3-34)Chairs: Egidio Del Fabbro, Joanna Lima
  • Poster session 4.3 · Muscle Wasting & Sarcopenia (posters 4-13 to 4-24)Chairs: Benjamin Miller, Ilse Vanhorebeek
10:00–11:15
SESSION 26 · HALL A · Clinical

GLP-1RA for weight loss therapy: the issue of muscle and bone loss

Chairs
Stefan Anker, Germany; Andrew Coats, Australia; Bo Falck Hansen, Denmark

  • Sex-dependent decreases in organ weight with GLP-1RAKatsu Funai, USA
  • Henning Langer
    Liver, heart and bone during incretin treatmentHenning Langer, Germany
  • David Glass
    Myostatin/activin-pathway combination-therapy trial data (e.g., bimagrumab + GLP-1 agonist)David Glass, USA
  • Mitchell Steiner
    The experience with enobosarmMitchell Steiner, USA
  • Ken Attie
    Beyond lean mass preservation: Cardiometabolic effects of anabolic add-on therapies for weight lossKen Attie, USA
  • Discussion
SESSION 27 · HALL B · Basic

From signals to systemic wasting: crosstalk in cancer cachexia

Chairs
Lynda Bonewald, USA; Marcus Goncalves, USA

  • Impaired T cell functionality contributes to cancer cachexiaSu-Ping Ng, Germany
  • Tumor-secreted ADAMTSL4 activates latent TGF-β1 to drive cancer cachexiaMauricio Berriel Diaz, Germany
  • Alessio Molfino
    The adipose tissue as an active driver of cancer and cachexia progression: depot-specific features and novel targetsAlessio Molfino, Italy
  • James Carson
    The gonad-bone-muscle axis in cancer and treatment-induced cachexiaJames Carson, USA
  • Discussion
11:25–12:55
SESSION 28 · HALL A

Late breaking science & trials

Chairs
To be announced; To be announced

  • A) Sarcopenia related
  • PEP-421, a novel ultra-long-acting CRHR2 agonist, promotes weight loss while preserving skeletal muscle during semaglutide treatment (7-14)Keld Fosgerau, Denmark
  • Assessment of lean mass, skeletal muscle volume and strength from a 12-week Phase 1 randomized controlled trial using trevogrumab, a myostatin inhibitor, in healthy older adults (4-21)Jennifer Lighter, USA
  • RJx-01 improves recovery of muscle strength and function following immobilization in older adults: integrated clinical and transcriptomic evidence from a Phase 1b trial (7-01)Jeroen Aerssens, Belgium
  • MF-300 in age-related sarcopenia: a Phase 2b design evaluating physical function, muscle strength and patient-reported outcomes (7-03)Jose Garcia, USA
  • B) Cancer cachexia related
  • A Phase 1b dose escalation study of an anti-GDF-15 monoclonal antibody, Rilogrotug (Rilo, AV-380), for cancer cachexia (7-04)Eric Roeland, USA
  • REACH (Rilogrotug TrEatment of Anorexia in Cancer CacHexia): a randomized, double-blind study of rilogrotug versus placebo in patients with cancer cachexia and metastatic colorectal cancer (mCRC) or metastatic non-small cell lung cancer (mNSCLC) (3-20)Claudia Lebedinsky, USA
  • IMPACT-ONE: design of a randomized, double-blind, placebo-controlled Phase 2b trial of (S)-pindolol benzoate on body weight and functional outcomes in patients with cachexia due to non-small cell lung cancer (7-02)Uwe Pelzer, Germany
  • Efficacy and safety of ponsegromab in non-small cell lung cancer and cachexia: a subgroup analysis of PROACC-1 phase 2 study (3-24)Jeffrey Crawford, USA
  • Discussion
SESSION 29 · 11:25–12:40 · HALL B · Basic

Neural inflammatory and behavioral axes in cachexia

Chairs
Laure Bindels, Belgium; Alessio Molfino, Italy

  • Mechanisms of behavioral changes in cachexiaTobias Janowitz, USA
  • Xiling Shen
    Targeting the peripheral and systemic gut-brain axes to combat cachexiaXiling Shen, USA
  • Eileen White
    Metabolism and behavior in cancer cachexiaEileen White, USA
  • Aaron Grossberg
    Sympathetic nerve mediated factors in cachexiaAaron Grossberg, USA
  • Discussion
12:50–13:50

Industry session · Lunch

13:00–13:50

Ken Fearon Career Café · Meet the Mentor (attendance upon application and confirmation)

14:00–15:15
SESSION 30 · HALL A · Translational

Emerging treatments in neuromuscular disease

Chairs
David Glass, USA; Fabio Dorigotti, Switzerland

  • Fibroadipogenic progenitors as a therapeutic target in dystrophic muscleMarshall Hogarth, USA
  • (s)-oxprenolol for ALSJochen Springer, Germany
  • Anti-inflammatory strategies in neuromuscular diseaseAgata Mossakowski, Germany
  • Genetic modifiers in neuromuscular diseasesAlexis Demonbreun, USA
  • Discussion
SESSION 31 · HALL B · Translational

Bone–muscle crosstalk in cachexia and sarcopenia

Chairs
Kamal Awad, USA; Gustavo Duque, Canada

  • Lynda Bonewald
    General bone–muscle crosstalk: mechanisms and implicationsLynda Bonewald, USA
  • Andrea Bonetto
    Liver-bone-muscle-cancer interactions: clinical perspectives and therapeutic opportunitiesAndrea Bonetto, USA
  • Fabrizio Pin
    Osteocyte mediated bone-muscle crosstalk in cancer cachexiaFabrizio Pin, USA
  • Marco Brotto
    Integrative musculoskeletal biomarkers: myokines, osteokines, and beyond in sarcopenia and osteoporosisMarco Brotto, USA
  • Discussion
15:15–16:00

Highlights session · Hall A · Chairs: Teresa Zimmers, USA; Maurizio Muscaritoli, Italy. Basic science: Aaron Grossberg, USA. Sarcopenia: to be announced. Cancer cachexia: Brittany Counts, USA. Poster Award · Young Investigator Award · Farewell.

Be part of the scientific exchange.

SCWD 2026 · Washington, DC · December 10–12

Register in person

Bring your questions to Washington.

Meet the people investigating them.

View registration

Meet the science.
Meet the people.

Featured contributors listed in the 2026 scientific programme.

Teresa Zimmers

Teresa Zimmers

OHSU Knight Cancer Institute, Oregon Health & Science University

Responder analysis in the PACTO trial
Kamyar Kalantar-Zadeh

Kamyar Kalantar-Zadeh

UCLA David Geffen School of Medicine · Harbor-UCLA Medical Center

Cachexia in CKD and AKI
Eric Roeland

Eric Roeland

OHSU Knight Cancer Institute, Oregon Health & Science University

GDF15 inhibition to reduce cachexia and promote anti-tumor therapy
Marilia Seelaender

Marilia Seelaender

University of São Paulo · Faculty of Medicine

Cachexia as multi-organ disease

Find your next conversation.

Posters, rapid-fire abstracts, the Career Café and the welcome reception bring people together beyond the sessions.

Plan your participation

SCWD 2026.
Be there in person.

December 10–12 · Washington, DC

Join clinicians and researchers for three days dedicated to cachexia, sarcopenia and wasting disorders.

Registration and ticket options are available on the official SCWD website.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!